Filtering by: Buprenorphine

Sep
24
12:00 PM12:00

CDIAS PSMG: Stephen Martin and Stephanie Strong

Better, Faster, Cheaper, and Scaled: Opioid Use Disorder Treatment in the Fentanyl Era

Stephen Martin, MD, EdM
Boulder Care

Stephanie Strong, CEO, Founder
Boulder Care

ABSTRACT:
Treating opioid use disorder may be described as a “strike while the iron’s hot” scenario. Treatment must occur before doubts, withdrawal, or challenging life circumstances overwhelm someone who is interested, closing the window of opportunity. Despite nationwide efforts to expand access to highly effective medications like methadone and buprenorphine, both remain underused due to a combination of regulatory and attitudinal barriers. These barriers manifest in long wait-times (a problem of timing) and treatment scarcity (a problem of scale).

View Event →
Feb
27
12:00 PM12:00

C-DIAS PSMG: Karen Osilla

It takes a village: Implementing a pragmatic trial to evaluate a group telehealth intervention for family members affected by opioid use disorder

Karen Osilla, PhD
Stanford University School of Medicine

ABSTRACT:
Opioid use disorder (OUD) has devastating effects on individuals, families, and communities. This presentation describes eINSPIRE (INtegrating Support Persons Into REcovery), a pragmatic randomized trial that tests the Community Reinforcement Approach and Family Training (CRAFT) intervention delivered via group telehealth therapy compared to usual care. CRAFT is an evidence-based approach for the family members or close friends (referred to as Support Persons; SPs) of individuals with a substance use disorder. Patients and SP dyads were recruited across five community health systems in Southern and Northern California that provide buprenorphine treatment and mental health services. This presentation will describe our dyadic recruitment and implementation insights on the adoption, reach, and feasibility of intervening with SPs in these settings.

View Event →